A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Clinical trial NCT07190196 · RECRUITING
Trial details
- NCT number
- NCT07190196
- Sponsor
- Sanofi
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-26
- Primary completion
- 2028-06-28
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.